<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03172819</url>
  </required_header>
  <id_info>
    <org_study_id>EPOC1505</org_study_id>
    <nct_id>NCT03172819</nct_id>
  </id_info>
  <brief_title>Special Combination of OBP-301 and Pembrolizumab</brief_title>
  <official_title>An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Toshihiko Doi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oncolys BioPharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center Hospital East</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicenter, open-label Phase I study to exploratively evaluate the efficacy and&#xD;
      safety of OBP-301 in combination with Pembrolizumab in patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1a part:&#xD;
&#xD;
      To evaluate safety and tolerability in combination of OBP-301 and Pembrolizumab in patient&#xD;
      with advanced or metastatic solid tumor and to determine recommended dose in phase 1b part.&#xD;
&#xD;
      Phase 1b part:&#xD;
&#xD;
      To evaluate safety and potential efficacy in combination of OBP-301 and Pembrolizumab in&#xD;
      patients in expanded arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>4weeks</time_frame>
    <description>Dose limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (RR)</measure>
    <time_frame>3 years</time_frame>
    <description>Response rate by RECIST ver. 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse event</measure>
    <time_frame>3 years</time_frame>
    <description>Rate of adverse event</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers:Efficacy evaluations according to immune status</measure>
    <time_frame>3 years</time_frame>
    <description>Immune status will be analyzed using biopsy and blood samples by flow cytometry, RNA seq, whole exome sequencing, and immunohistochemistry, etc.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>OBP-301+Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OBP-301+Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OBP-301</intervention_name>
    <description>Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.&#xD;
Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.&#xD;
The patients in Phase 1a, Pembrolizumab administration has continued, are included.&#xD;
The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles.</description>
    <arm_group_label>OBP-301+Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.</description>
    <arm_group_label>OBP-301+Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          2. Be &gt;=18 years of age on the day of signing the informed consent.&#xD;
&#xD;
          3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.&#xD;
&#xD;
          4. Have histologically or cytologically confirmed advanced or metastatic solid tumor with&#xD;
             possibility of intratumoral injection, for which no effective standard therapy exists&#xD;
             or standard therapy has failed.&#xD;
&#xD;
          5. Have one or more evaluable lesions based on RECIST 1.1&#xD;
&#xD;
             *Evaluable lesions: measurable lesion and/or non-measurable lesion&#xD;
&#xD;
          6. Be willing to provide tissue; newly obtained endoscopic biopsy specimens or&#xD;
             formalin-fixed, paraffin-embedded (FFPE) block specimens.&#xD;
&#xD;
          7. Female subjects of childbearing potential have a negative urine or serum pregnancy&#xD;
             test within 7 days prior to enrollment. If the urine test is positive or cannot be&#xD;
             confirmed as negative, a serum pregnancy test will be required. It is allowed that the&#xD;
             test at the same day at 7 days prior to enrollment. And male / female subjects of&#xD;
             childbearing potential must be agree to use an adequate method of contraception&#xD;
             starting with signing the informed consent through 120 days after the last dose of&#xD;
             study medication.&#xD;
&#xD;
          8. Demonstrated adequate organ function as defined in following criteria. All screening&#xD;
             labs should be performed within 7 days of enrollment. It is allowed that the labs at&#xD;
             the same day at 7days prior to enrollment.&#xD;
&#xD;
        Note: Subject must not have taken transfusion, hematopoietic agent; granulocyte-colony&#xD;
        stimulating factor (G-CSF) etc., and/or oxygen inhalation within 7 days before the&#xD;
        screening labs.&#xD;
&#xD;
          1. Absolute neutrophil count (ANC)&gt;=1,500 /mm3&#xD;
&#xD;
          2. Platelets&gt;=100,000 /mm3&#xD;
&#xD;
          3. Hemoglobin&gt;=9.0 g/dL&#xD;
&#xD;
          4. Serum total bilirubin&lt;=2.0 mg/dL&#xD;
&#xD;
          5. aspartate aminotransferase (AST) (SGOT) and alanine aminotransferase (ALT) (SGPT)&lt;=100&#xD;
             IU/L for subjects with liver metastases&lt;=200 IU/L&#xD;
&#xD;
          6. Serum creatinine&lt;= 1.5 mg/dL; or if serum creatinine &gt; 1.5 mg/dL, creatinine/clearance&#xD;
             &gt;=60 mL/min (Cockcroft-Gault formula)&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy within 4 weeks of study Day 1.&#xD;
&#xD;
          2. Has an active autoimmune disease that has required systemic treatment in past 2 years.&#xD;
&#xD;
          3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to study Day 1.&#xD;
&#xD;
          4. Has known active central nervous system metastases and/or carcinomatous meningitis.&#xD;
&#xD;
          5. Has had prior anti-cancer monoclonal antibody chemotherapy, targeted small molecule&#xD;
             therapy, or radiation therapy within 2 weeks prior to study Day 1 or immunotherapy&#xD;
             targeted to Programmed cell death 1 (PD-1), PD-L1, PD-L2 within 4 weeks prior to Da y&#xD;
             1 or OBP-301 study, who has not recovered from adverse events due to a previously&#xD;
             administered agent.&#xD;
&#xD;
          6. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
&#xD;
          7. Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
&#xD;
          8. Has a known history of Human Immunodeficiency Virus.&#xD;
&#xD;
          9. Has known active Hepatitis B or Hepatitis C.&#xD;
&#xD;
         10. Has known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
         11. Has an active infection requiring systemic therapy.&#xD;
&#xD;
         12. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         13. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the screening visit through 120 days&#xD;
             after the last dose of trial treatment.&#xD;
&#xD;
         14. Previous severe hypersensitivity to another monoclonal antibody&#xD;
&#xD;
         15. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshihiko Doi, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Center Hospital East</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 30, 2017</study_first_submitted>
  <study_first_submitted_qc>May 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2017</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center Hospital East</investigator_affiliation>
    <investigator_full_name>Toshihiko Doi</investigator_full_name>
    <investigator_title>Chief / Division of experimental therapeutics</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

